Dosing 6-Thioguanine in Inflammatory Bowel Disease: Expert-Based Guidelines for Daily Practice

Authors

  • Margien L Seinen VU University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands
  • Dirk P. van Asseldonk VU University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands
  • Chris J J Mulder VU University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands
  • Nanne K H de Boer VU University Medical Centre, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands

Keywords:

6-thioguanine, Crohn's disease, ulcerative colitis, thiopurines, side-effects, nodular regenerative hyperplasia, guidelines

Abstract

Conventional thiopurines are considered to be effective and safe in the treatment of inflammatory bowel disease (IBD) patients; unfortunately more than 50% of patients discontinue thiopurine therapy, mainly due to the development of intractable adverse events. In recent years, the use of 6-thioguanine has been proposed as an alternative thiopurine in IBD patients failing to tolerate or to respond to conventional thiopurine therapy. In this clinical review, we describe the rationale for 6-thioguanine therapy and discuss the reported hepatotoxicity of 6-thioguanine (especially nodular regenerative hyperplasia). We propose expert-based guidelines for balanced treatment.

Downloads

Published

2010-09-01

How to Cite

1.
Seinen ML, van Asseldonk DP, Mulder CJJ, de Boer NKH. Dosing 6-Thioguanine in Inflammatory Bowel Disease: Expert-Based Guidelines for Daily Practice. JGLD [Internet]. 2010 Sep. 1 [cited 2025 Jun. 15];19(3):291-4. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/2010.3.12

Issue

Section

Reviews